ASH 2018 | Exploring the use of atezolizumab in combination with R-CHOP in DLBCL
After the successful use of PD-L1 inhibitors in solid tumors, these agents are now being explored in diffuse large B-cell lymphoma (DLBCL). Here, Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the preliminary analysis of a Phase I/II study on the use of atezolizumab in combination with R-CHOP in patients with DLBCL (NCT02596971). Presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up